Clinical Trials
329 trialsVon Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
DESCENT-1
A2 Biotherapeutics Inc.
Study of Kidney Tumors in Younger Patients
Children's Oncology Group
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
National Cancer Institute (NCI)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
ITHORinVHL
IRCCS San Raffaele
PEP-C
Centre Hospitalier Universitaire de Saint Etienne
DP-04
AstraZeneca
CABOCARE
Ipsen
REPLICA
Ipsen
BASECAMP-1
A2 Biotherapeutics Inc.
ELEPHAS-02
Elephas
RCCETT
Peking University Third Hospital
ZEBRA
Istituto Oncologico Veneto IRCCS
TraveraRTGx
Travera Inc
VolUS3D
Assistance Publique - Hôpitaux de Paris
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
University of Southern California
PP-RECURK
Gødstrup Hospital
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Tel-Aviv Sourasky Medical Center
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
The Christie NHS Foundation Trust
KIDCaD
Charles University, Czech Republic
TARGET-RCC
IRCCS San Raffaele
RASROP-003
Humanitas Hospital, Italy
ELEPHAS-04
Mayo Clinic
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
ADONIS
Pfizer
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Pfizer
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
Mayo Clinic
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
ODYSSEY RCC
Duke University
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
COSTAR
Peking University First Hospital
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Institutes of Health Clinical Center (CC)
Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
First Affiliated Hospital of Fujian Medical University
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
Children's Hospital Medical Center, Cincinnati
PET/MR for Characterization of Renal Masses (RMs)
University of Texas Southwestern Medical Center
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Mayo Clinic
RREIN
University Hospital, Lille
Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy
Jinling Hospital, China
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Jinling Hospital, China
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Jinling Hospital, China
AURICRE
University of Yamanashi
Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
International Multicentric Study ARON-1
Hospital of Macerata
NEUTROFLOW
OncoHost Ltd.